Sept 26 (Reuters) - Shares of BioAge Labs
opened 25% above their initial public offering price in their
Nasdaq debut on Thursday, valuing the weight-loss drug developer
at $757.5 million.
(Reporting by Arasu Kannagi Basil, Prakhar Srivastava, Puyaan
Singh and Niket Nishant in Bengaluru; Editing by Sriraj
Kalluvila)